Dr. Mary Reyland at the University of Colorado has discovered that the use of Tyrosine Kinase Inhibitors before and during cancer therapy leads to protection and regeneration of the salivary glands, while not interfering with the cancer therapy. By treating non-cancerous cells or mice with commercially available TKIs in combination with traditional cancer therapies (i.e. radiation or chemotherapy), normal cells and tissues are less sensitive to apoptotic stimuli, and also undergo higher levels of regeneration and functional recovery. This new treatment would be particularly helpful to head and neck cancer patients suffering from dry mouth syndromes (xerostomia).
Download Summary Document Here:
http://cuamc.technologypublisher.com/files/sites/market_summary_cu4354h.pdf